Since many ICI-based immunotherapies rely on the tumour-specific PD-1+CD8+ TILs, their lacking in high-risk “Infiltrating” HPV− HNSCC may exacerbate the resistance of these HNSCCs to immunotherapy. Here, CD8A is linked to neoplasm.